[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354144-105":59,"doc-detail-354144-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-aldh7a1-with-covalent-inhibitors-reveals-new-chemical-space-for-prostate-cancer-therapy","Targeting ALDH7A1 with covalent inhibitors reveals new chemical space for prostate cancer therapy","","Prostate cancer (Pca) remains a major global health burden. Androgen deprivation and receptor-targeted therapies often provide initial benefit, but resistance can drive metastatic castration-resistant Pca with limited options. Aldehyde dehydrogenase 7a1 (ALDH7A1) is an emerging oncogenic driver, yet selective inhibitors are lacking. The study reports irreversible ALDH7A1 inhibitors covalently targeting catalytic Cys330, showing selectivity over ALDH4A1 and GApDH, reduced DU145 viability and migration, altered cell cycle, and increased oxidative stress signaling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-aldh7a1-with-covalent-inhibitors-reveals-new-chemical-space-for-prostate-cancer-therapy/354144/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-aldh7a1-with-covalent-inhibitors-reveals-new-chemical-space-for-prostate-cancer-therapy/354144.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are ALDH7A1 inhibitors being explored for prostate cancer therapy?","Question",{"text":112,"@type":113},"ALDH7A1 is described as an emerging oncogenic driver in prostate cancer, and selective inhibitors were reported as lacking. Targeting it is proposed to help address therapy resistance, particularly in metastatic castration-resistant disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do the reported inhibitors act on ALDH7A1?",{"text":117,"@type":113},"The inhibitors are reported as irreversible covalent compounds that target the catalytic Cys330. They were identified from a library of 3-bromo-4,5-dihydroisoxazole derivatives.",{"name":119,"@type":110,"acceptedAnswer":120},"What selectivity and cellular effects were observed in the study?",{"text":121,"@type":113},"The compounds showed minimal inhibition of ALDH4A1 and GApDH, supporting ALDH7A1 selectivity. In DU145 cells, compounds 3b and 4b reduced viability, impaired migration, altered the cell cycle, inhibited intracellular ALDH activity, and increased malondialdehyde accumulation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354144,1790906884,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Journal of EnzymE InhIbItIon and mEdIcInal chEmIstry 2026, Vol. 41, no. 1, 2664708  \n[https://doi.org/10.1080/14756366.2026.2664708](https://doi.org/10.1080/14756366.2026.2664708)  \nReseaRch aRticle    \nTargeting ALDH7A1 with covalent inhibitors reveals new chemical space for prostate cancer therapy  \nRaffaella Galloa\\#, antonio scaranob\\#, eleonora Gianquintoc, Gaia Franzinid, Giulia antoninie, serena Montalbanoe, camillo Palmieria, Paola contie, Francesca spyrakisc, chiara Borsarie and stefano Brunob,d  \nadepartment of Experimental and clinical medicine,“magna Græcia” university of catanzaro, catanzaro, Italy; bdepartment of food and drug, university of Parma, Parma, Italy; cdepartment of drug science and technology, university of turin, turin, Italy; dbiopharmanet-tEc, university of Parma, Parma, Italy; edepartment of Pharmaceutical sciences, university of milan, milan, Italy  \nABSTRACT  \nProstate cancer (Pca) remains a major global health burden. although androgen deprivation and receptor-targeted therapies initially benefit patients, resistance often leads to metastatic castration-resistant prostate cancer, with limited treatment options. aldehyde dehydrogenase 7a1 (alDh7a1) is an emerging oncogenic driver of Pca, but selective inhibitors are [lacking. here](lacking. here), we report irreversible alDh7a1 inhibitors targeting the catalytic cys330, identified from a library of 3-bromo-4,5-dihydroisoxazole derivatives. these compounds show minimal inhibition of alDh4a1 and GaPDh, supporting selectivity for alDh7a1. compounds 3b and 4b reduced DU145 cell viability (low μMic50), impaired migration, and altered the cell cycle. No significant effects were observed in lNcaP cells (low alDh7a1 expression) or hs27 fibroblasts. treatment of DU145 cells resulted in the inhibition of intracellular alDh activity and accumulation of malondialdehyde, consistent with increased oxidative stress. these findings validate alDh7a1 as a druggable target and introduce a new chemical space for selective covalent alDh inhibitors in oncology.  \nGRAPHICAL ABSTRACT  \nARTICLE HISTORY  \nReceived 28 January 2026 Revised 2 april 2026 accepted 20 april 2026  \nKEYWORDS  \nalDh7a1 selective inhibition; covalent enzyme inhibitors; 3-halo- 4,5-dihydroisoxazoles; catalytic cysteine targeting; aldehyde dehydrogenase isoforms  \nCONTACT stefano bruno  [stefano.bruno@unipr.it](stefano.bruno@unipr.it)  dept. of food and drug, Parco area delle scienze 23\\a, Parma, Italy; chiara borsari  [chiara.borsari@unimi.it](chiara.borsari@unimi.it)  dept. of Pharmaceutical sciences, university of milan, Via mangiagalli 25, 20133 milan, Italy  \n\\#these authors contributed equally to this work.  \n supplemental data for this article can be accessed online at [https://doi.org/10.1080/14756366.2026.2664708](https://doi.org/10.1080/14756366.2026.2664708) .  \n© 2026 the author(s) . Published by Informa uK limited, trading as taylor & francis Group  \nthis is an open access article distributed under the terms of the creative commons attribution-noncommercial license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc/4.0/](by-nc/4.0/)), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. the termson which this article has been published allow the posting of the accepted manuscript in a repository by the author(s) or with their consent.  \n2  R. GallO et al.  \nIntroduction  \nProstate cancer (Pca) is the second most common type of cancer and the fifth leading cause of cancer-related mortality in men, with an estimated 1.5 million new cases and 397,000 deaths worldwide in 2022 alone1. Pca typically arises as a localised disease but may progress to a locally advanced stage involving adjacent tissues such as the bladder, seminal vesicles, or the rectum. in more aggressive cases, Pca can metastasise through the lymphatic system to distan","cbCaihwIHHgnMLd0","https://ap.wps.com/l/cbCaihwIHHgnMLd0","pdf",1748778,18,"English","# Abstract\n# Introduction\n## Targeting ALDH7A1 and therapeutic rationale\n## Aldehyde dehydrogenases and prostate cancer relevance","[{\"question\":\"Why are ALDH7A1 inhibitors being explored for prostate cancer therapy?\",\"answer\":\"ALDH7A1 is described as an emerging oncogenic driver in prostate cancer, and selective inhibitors were reported as lacking. Targeting it is proposed to help address therapy resistance, particularly in metastatic castration-resistant disease.\"},{\"question\":\"How do the reported inhibitors act on ALDH7A1?\",\"answer\":\"The inhibitors are reported as irreversible covalent compounds that target the catalytic Cys330. They were identified from a library of 3-bromo-4,5-dihydroisoxazole derivatives.\"},{\"question\":\"What selectivity and cellular effects were observed in the study?\",\"answer\":\"The compounds showed minimal inhibition of ALDH4A1 and GApDH, supporting ALDH7A1 selectivity. In DU145 cells, compounds 3b and 4b reduced viability, impaired migration, altered the cell cycle, inhibited intracellular ALDH activity, and increased malondialdehyde accumulation.\"}]","Targeting ALDH7A1 with covalent inhibitors reveals new chemical space for prostate cancer therapy | PDF",1790109224,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/448b208fbda42646599b14da45c0c9cc.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1362ce12bd5b336747ccc40003b4bac2.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff9cb6bb750e3e6d2f686a03723b88cd.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7aeaebc0c6e9e46be504733d97bd03dd.webp",980,1306]